business π Symbiotec Pharmalab IPO: Worth the hype?
Symbiotec Pharmalab, an API manufacturer, launched its IPO on August 24, 2026, with a total size of Rs 1,757 crore. The company operates globally, leading in corticosteroids and steroidal hormones, selling to over 200 customers. Currently, new plants are loss-making, and profit growth is slow despite strong market dominance. The IPO prices the company at around 58 times earnings, which is a demanding valuation. Investors must weigh its strong foundations against current operational drags.